Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

WASHINGTON, June 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced results of an insurance claims analysis related to babesiosis and chronic fatigue, as conducted by Komodo Health, a healthcare technology company that delivers the evidentiary standard for real-world data and analytics, contracted by the Company.

Read more at globenewswire.com